Nippon Shinyaku Co., Ltd.

Nippon Shinyaku manufactures and sells pharmaceuticals and foodstuffs in Japan and globally. Its operations are structured into Pharmaceuticals and Functional Food Business segments.

It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and diseases health food ingredients, preservatives, protein preparations, and supplements.

The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis RGX-121 for the treatment of mucopolysaccharidosis. Founded in 1911, Nippon Shinyaku is headquartered in Kyoto, Japan.